These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 18980549)

  • 41. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection.
    Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS
    J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bevacizumab 5 mg/kg can be infused safely over 10 minutes.
    Reidy DL; Chung KY; Timoney JP; Park VJ; Hollywood E; Sklarin NT; Muller RJ; Saltz LB
    J Clin Oncol; 2007 Jul; 25(19):2691-5. PubMed ID: 17602073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiogenesis inhibitors in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bevacizumab: current updates in treatment.
    Van Meter ME; Kim ES
    Curr Opin Oncol; 2010 Nov; 22(6):586-91. PubMed ID: 20811277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bevacizumab: a review of its use in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    Drugs; 2008; 68(4):487-506. PubMed ID: 18318567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report.
    Hurwitz HI; Honeycutt W; Haley S; Favaro J
    Clin Colorectal Cancer; 2006 May; 6(1):66-9. PubMed ID: 16796794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
    Ellis LM; Rosen L; Gordon MS
    Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab in colorectal cancer: current and future directions.
    Yeung Y; Tebbutt NC
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA
    Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
    Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
    J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tetany: possible adverse effect of bevacizumab.
    Anwikar SR; Bandekar MS; Patel TK; Patel PB; Kshirsagar NA
    Indian J Cancer; 2011; 48(1):31-3. PubMed ID: 21248449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
    Krämer I; Lipp HP
    Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].
    Manikhas GM; Korolenko VO; Al'-Nekhmi AA; Antimonik NIu
    Vopr Onkol; 2010; 56(5):613-6. PubMed ID: 21137245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
    Saif MW; Longo WL; Israel G
    Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.